Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis

Gastroenterology

Volumn 152, Issue 8, 2017, Pages 1889-1900.e9

  Shen, Nicole T ^a   Maw, Anna ^b   Tmanova, Lyubov L ^a   Pino, Alejandro ^c   Ancy, Kayley ^c   Crawford, Carl V ^a   Simon, Matthew S ^a   Evans, Arthur T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Antibiotic Associated Diarrhea; Lactobacillus; Meta analysis; Nosocomial Infection

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COCHRANE LIBRARY; EMBASE; FEVER; FLATULENCE; HUMAN; INCIDENCE; INFECTION PREVENTION; LACTOBACILLUS; MEDLINE; NAUSEA; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TASTE DISORDER; ADULT; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL TRACT; HOSPITALIZATION; INTESTINE FLORA; META ANALYSIS; MICROBIOLOGY; ODDS RATIO; PATHOGENICITY; PATHOPHYSIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HOSPITALIZATION; HUMANS; INCIDENCE; ODDS RATIO; PROBIOTICS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85018490434     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.02.003     Document Type: Article

References (53)

1. Lessa, F.C., Mu, Y., Bamberg, W.M., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 825–834.
2. Evans, C.T., Safdar, N., Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis 60:Suppl 2 (2015), S66–S71.
3. Kelly, C.P., A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA 301 (2009), 954–962.
4. Fridkin, S., Baggs, J., Fagan, R., et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep 63 (2014), 194–200.
5. Wu, S.-Y., Green, A., Projection of Chronic Illness Prevalence and Cost Inflation. 2000, RAND Health, Santa Monica, CA, 18.
6. Silva, M.J., Carneiro, M.B., dos Anjos Pultz, B., et al. The multifaceted role of commensal microbiota in homeostasis and gastrointestinal diseases. J Immunol Res, 2015, 2015, 321241.
7. US Department of Health and Human Services, National Institutes of Health. National Center for Complementary and Integrative Health (NCCIH). Probiotics. Volume 2016. Available at: https://nccih.nih.gov/health/probiotics/introduction.htm#hed3. Accessed April 3, 2016.
8. McFarland, L.V., From yaks to yogurt: the history, development, and current use of probiotics. Clin Infect Dis 60:Suppl 2 (2015), S85–S90.
9. Forssten, S., Evans, M., Wilson, D., et al. Influence of a probiotic mixture on antibiotic induced microbiota disturbances. World J Gastroenterol 20 (2014), 11878–11885.
10. Carasi, P., Trejo, F.M., Perez, P.F., et al. Surface proteins from Lactobacillus kefir antagonize in vitro cytotoxic effect of Clostridium difficile toxins. Anaerobe 18 (2012), 135–142.
11. Castagliuolo, I., Riegler, M.F., Valenick, L., et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67 (1999), 302–307.
12. Solomon, K., The host immune response to Clostridium difficile infection. Ther Adv Infect Dis 1 (2013), 19–35.
13. Vinderola, G., Matar, C., Perdigon, G., Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors. Clin Diagn Lab Immunol 12 (2005), 1075–1084.
14. Johnston, B.C., Ma, S.S., Goldenberg, J.Z., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 157 (2012), 878–888.
15. Goldenberg Joshua, Z., Ma Stephanie, S.Y., Saxton Jane, D., et al. Probiotics for the prevention of Clostridium Difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev(5), 2013 May 31, CD006095.
16. Lau, C.S., Chamberlain, R.S., Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med 9 (2016), 27–37.
17. Goldstein, E.J., Johnson, S., Maziade, P.J., et al. Pathway to Prevention of nosocomial Clostridium difficile infection. Clin Infect Dis 60:Suppl 2 (2015), S148–S158.
18. Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498.
19. Cohen, S.H., Gerding, D.N., Johnson, S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31 (2010), 431–455.
20. Allen, S.J., Wareham, K., Wang, D., et al. Lactobacilli and Bifidobacteria in the Prevention of Antibiotic-Associated Diarrhoea and Clostridium Difficile Diarrhoea in Older Inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382 (2013), 1249–1257.
21. Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269 W64.
22. Higgins, J.P.T., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], 2011, The Cochrane Collaboration Available at http://handbook.cochrane.org Accessed April 19, 2017.
23. Higgins, J.P., Altman, D.G., Gotzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
24. Guyatt, G.H., Oxman, A.D., Vist, G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926.
25. Akl, E.A., Briel, M., You, J.J., et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ, 344, 2012, e2809.
26. Chaimani, A., Higgins, J.P., Mavridis, D., et al. Graphical tools for network meta-analysis in STATA. PLoS One, 8, 2013, e76654.
27. Langan, D., Higgins, J.P., Gregory, W., et al. Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol 65 (2012), 511–519.
28. Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994), 1088–1101.
29. Egger, M., Davey Smith, G., Schneider, M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
30. Gao, X.W., Mubasher, M., Fang, C.Y., et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 105 (2010), 1636–1641.
31. Ouwehand, A.C., DongLian, C., Weijian, X., et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine 32 (2014), 458–463.
32. Miller, M., Florencio, S., Eastmond, J., Reynolds, S., Results of 2 prospective randomized studies of Lactobacillus GG to prevent C difficile infection in hospitalized adults receiving antibiotics [Abstract]. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 48 (2008), 578–579.
33. Surawicz, C.M., Elmer, G.W., Speelman, P., et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 96 (1989), 981–988.
34. McFarland, L.V., Surawicz, C.M., Greenberg, R.N., et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90 (1995), 439–448.
35. Can, M., Besirbellioglu, B.A., Avci, I.Y., et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit 12 (2006), PI19–PI22.
36. Pozzoni, P., Riva, A., Bellatorre, A.G., et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 107 (2012), 922–931.
37. Ehrhardt, S., Guo, N., Hinz, R., et al. Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis, 3, 2016, ofw011.
38. Thomas, M.R., Litin, S.C., Osmon, D.R., et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clinic Proc 76 (2001), 883–889.
39. Safdar, N., Barigala, R., Said, A., et al. Feasibility and tolerability of probiotics for prevention of antibiotic-associated diarrhoea in hospitalized US military veterans. J Clin Pharm Ther 33 (2008), 663–668.
40. Wong, S., Jamous, A., O'Driscoll, J., et al. A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial. Br J Nutr 111 (2014), 672–678.
41. Beausoleil, M., Fortier, N., Guenette, S., et al. Effect of a fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 21 (2007), 732–736.
42. Plummer, S., Weaver, M.A., Harris, J.C., et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 7 (2004), 59–62.
43. Wenus, C., Goll, R., Loken, E.B., et al. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr 62 (2008), 299–301.
44. Hickson, M., D'Souza, A.L., Muthu, N., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335 (2007), 80–83.
45. Rafiq, R., Pandey, D., Osman, S.M., et al. Prevention of Clostridium difficile (C difficile) diarrhea with probiotic in hospitalized patients treated with antibiotics [Abstract]. Gastroenterology, 132(Suppl 2), 2007, A187.
46. Selinger, C.P., Bell, A., Cairns, A., et al. Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. J Hosp Infect 84 (2013), 159–165.
47. Dubberke, E.R., Reske, K.A., Olsen, M.A., et al. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 46 (2008), 497–504.
48. O'Brien, J.A., Lahue, B.J., Caro, J.J., et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 28 (2007), 1219–1227.
49. Kyne, L., Hamel, M.B., Polavaram, R., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34 (2002), 346–353.
50. Snydman, D.R., The safety of probiotics. Clin Infect Dis 46:Suppl 2 (2008), S104–S111 discussion S144–S151.
51. Rosner, B., Fundamentals of Biostatistics. 2011, Brooks/Cole, Cengage Learning, Boston.
52. Lenoir-Wijnkoop, I., Nuijten, M.J., Craig, J., et al. Nutrition economic evaluation of a probiotic in the prevention of antibiotic-associated diarrhea. Front Pharmacol, 5, 2014, 13.
53. Leal, J.R., Heitman, S.J., Conly, J.M., et al. Cost-effectiveness analysis of the use of probiotics for the prevention of clostridium difficile-associated diarrhea in a provincial healthcare system. Infect Control Hosp Epidemiol, 2016, 1–8.